Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines

• US 20050153947A1
• Filed: 09/20/2004
• Published: 07/14/2005
• Est. Priority Date: 09/24/2002
• Status: Abandoned Application

• Current Assignee: Combinatorx (Singapore) Pte., Ltd.
• Original Assignee: Combinatorx (Singapore) Pte., Ltd.
• Inventors: Sachs, Noah, Zimmerman, Grant R., Manivasakam, Palaniyandi, Keith, Curtis, Jost-Price, Edward Roydon, Smith, Brendan, Chappell, Todd W., Brasher, Bradley B., Nichols, M. James, Auspitz, Benjamin A., Fong, Jason, Padval, Mahesh
• Application Number:
  US10/947,455
• Publication Number:
  US 20050153947A1
• Time in Patent Office: Days
• US Class Current: 514/171
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 31/565 not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
• CPC Class Codes: A61K 38/13 Cyclosporins
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 9/0073 Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M
• CPC Class Codes: A61K 9/209 containing drug in at least two layers or in the core and in at least one outer layer

Abstract

The invention features a method for treating a patient diagnosed with, or at risk of developing, an immunoinflammatory disorder by administering an SSRI or analog or metabolite thereof and, optionally, a corticosteroid or other compound to the patient. The invention also features a pharmaceutical composition containing an SSRI or analog or metabolite thereof and a corticosteroid or other compound for the treatment or prevention of an immunoinflammatory disorder.

Claims

1. A composition comprising a selective serotonin reuptake inhibitor (SSRI) or analog thereof and a corticosteroid in amounts that together are sufficient in vivo to decrease proinflammatory cytokine secretion or production or to treat an immunoinflammatory disorder.

2-86. -86. (canceled)

87. A bilayer tablet comprising a) paroxetine and b) prednisolone, wherein said prednisolone is formulated for sustained release such that the T_max of said predsnisolone and the T_max said paroxetine are each 5 to 10 hours.